{"organizations": ["VIVUS Inc"], "uuid": "c5ebc6ae1c2214e1803fc88b7991afe209e672e0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "us.rd.yahoo.com", "main_image": "", "site_section": "http://finance.yahoo.com/rss/headline?s=VVUS", "section_title": "Yahoo! Finance: VVUS News", "url": "http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/cc/0/146160.html", "country": "GB", "title": "VIVUS Inc Earnings Call scheduled for 4:30 pm ET today", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "VIVUS Inc Earnings Call scheduled for 4:30 pm ET today", "spam_score": 0.0, "site_type": "news", "published": "2015-07-30T23:30:00.000+03:00", "replies_count": 0, "uuid": "c5ebc6ae1c2214e1803fc88b7991afe209e672e0"}, "author": "", "url": "http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/cc/0/146160.html", "ord_in_thread": 0, "title": "VIVUS Inc Earnings Call scheduled for 4:30 pm ET today", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "VIVUS Inc Earnings Call (Q2 2015) Thu, Jul 30, 2015, 4:30 pm Eastern \nListen to the archived event audio About VIVUS Inc ( VVUS ) VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California. Copyright © 2015 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service Copyright © 2015 FirstCall Events . Historical chart data provided by Commodity Systems, Inc. (CSI) . Company profile information presented on this page is Copyright Capital IQ . Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.", "external_links": [], "published": "2015-07-30T23:30:00.000+03:00", "crawled": "2015-07-31T03:18:56.708+03:00", "highlightTitle": ""}